SCHEDULE: Transcend Partners Amends IN8BIO Stake to 2.6%

Transcend Partners Opportunity Fund I LLC has filed an Amendment No. 2 to its Schedule 13G, disclosing a 2.6% beneficial ownership stake in IN8BIO, INC.

Summary

• Transcend Partners Opportunity Fund I LLC reported beneficial ownership of 107,416 shares of IN8BIO, INC. Common Stock.
• This ownership represents 2.6% of IN8BIO, INC.'s outstanding Common Stock.
• The percentage is calculated based on 4,078,139 shares of Common Stock outstanding as of June 30, 2025, as reported in IN8BIO's Quarterly Report on Form 10-Q filed on August 7, 2025.
• Transcend Partners Opportunity Fund I LLC holds shared voting and dispositive power over all 107,416 shares.
• The managing members of Transcend, Grant Fairbairn, Nina Fairbairn, and Scott Kintz, disclaim beneficial ownership of these shares.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating a change from a previous filing.

Sentiment

Score: 5

Explanation: The filing is a neutral disclosure of beneficial ownership, providing factual information without indicating positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by an investment fund in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the ownership stake itself.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant, though non-controlling, ownership stake by an investment fund.

Key Dates

Keywords

IN8BIO, Transcend Partners, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Investment Fund, SEC Filing